Zhong, M., van der Walt, A., Stankovich, J., Kalincik, T., Buzzard, K., Skibina, O., Boz, C., Hodgkinson, S., Slee, M., Lechner-Scott, J., Macdonell, R., Prevost, J., Kuhle, J., Laureys, G., Van Hijfte, L., Alroughani, R., Kermode, A. G., Butler, E., Barnett, M., Eichau, S., van Pesch, V., Grammond, P., McCombe, P., Karabudak, R., Duquette, P., Girard, M., Taylor, B., Yeh, W., Monif, M., Gresle, M., Butzkueven, H., & Jokubaitis, V. G. (2022). prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple sclerosis, 28, 958–969. http://access.bl.uk/ark:/81055/vdc_100147707853.0x000024